# **PRODUCT** INFORMATION



## Blonanserin

Item No. 16480

| CAS Registry No.: | 132810-10-7                                     | F             |
|-------------------|---|---------------|
| Formal Name:      | 2-(4-ethyl-1-piperazinyl)-4-                    |               |
|                   | (4-fluorophenyl)-5,6,7,8,9,10-                  |               |
|                   | hexahydro-cycloocta[b]pyridine                  |               |
| Synonyms:         | AD5423, Lonasen                                 |               |
| MF:               | C <sub>23</sub> H <sub>30</sub> FN <sub>3</sub> |               |
| FW:               | 367.5   |               |
| Purity:           | ≥98%  |               |
| UV/Vis.:          | λ <sub>max</sub> : 236, 315 nm                  |               |
| Supplied as:      | A crystalline solid                             |               |
| Storage:          | -20°C   | N N           |
| Stability:        | ≥4 years  | $\sim$ $\sim$ |

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

#### Laboratory Procedures

Blonanserin is supplied as a crystalline solid. A stock solution may be made by dissolving the blonanserin in the solvent of choice, which should be purged with an inert gas. Blonanserin is soluble in organic solvents such as ethanol and dimethyl formamide. The solubility of blonanserin in these solvents is approximately 10 and 15 mg/ml, respectively.

#### Description

Blonanserin is a 4-phenyl-2-(1-piperazinyl) pyridine that acts as an antagonist at dopamine D<sub>2</sub>, D<sub>3</sub>, and serotonin 5-HT<sub>2A</sub> receptors (K<sub>i</sub>s = 0.14, 0.49, and 0.81 nM, respectively).<sup>1</sup> It binds to 5-HT<sub>6</sub> with a  $K_i$  value of 11.7 nM and demonstrates relatively low affinity for 5-HT<sub>2C</sub> (K<sub>i</sub> = 26.4 nM), adrenergic  $\alpha_1$  (K<sub>i</sub> = 26.7 nM), histamine H<sub>1</sub> (K<sub>i</sub> = 765 nM), and muscarinic M<sub>1</sub> receptors (K<sub>i</sub> = 100 nM).<sup>1</sup> Blonanserin was developed in Japan as a novel antipsychotic that displays 20- and 94-fold higher affinity for D<sub>2</sub> receptors compared to haloperidol (Item No. 12014) and risperidone (Item No. 13629), respectively.<sup>1</sup>

#### Reference

1. Tenjin, T., Miyamoto, S., Ninomiya, Y., et al. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr. Dis. Treat. 9, 587-594 (2013).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/04/2022

### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM